Physician profile
Willie J Session
NPI 1588627053
$6,398.37
in general payments reported to CMS, 2019-2025
31 companies · $533 in 2025
The $533 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $638 · 2021: $1,468 · 2022: $1,628 · 2023: $662 · 2024: $636 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,830.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,014.98 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $754.12 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $670.64 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $657.52 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $506.38 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $401.23 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $378.22 | 2019-2025 | Farxiga |
| Esperion Therapeutics, INC. | $290.02 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $269.21 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.15 | 2019-2025 | Jardiance |
| Pfizer INC. | $211.61 | 2020-2023 | |
| Novo Nordisk INC | $171.55 | 2021-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $102.40 | 2022-2025 | |
| Boston Scientific Corporation | $79.53 | 2019-2024 | Watchman Access System |
| Kiniksa Pharmaceuticals International, Plc | $79.41 | 2024 | Arcalyst |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $66.69 | 2024-2025 | Korlym |
| Regeneron Healthcare Solutions, INC. | $62.76 | 2019 | |
| Celgene Corporation | $61.97 | 2022 | |
| Lundbeck LLC | $58.25 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $43.58 | 2019-2021 | |
| Edwards Lifesciences Corporation | $43.56 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $42.25 | 2024 | Impella |
| Irhythm Technologies, INC. | $30.15 | 2024 | Zio Monitor, Zio Xt Patch |
| Genzyme Corporation | $29.77 | 2019-2024 | |
| United Therapeutics Corporation | $21.46 | 2023 | Tyvaso |
| Amarin Pharma, INC. | $20.83 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $19.41 | 2024 | |
| Amgen INC. | $18.62 | 2023 | Repatha |
| Medicomp INC | $15.30 | 2024 | Telepatch Cardiac Monitor |
| Alnylam Pharmaceuticals INC. | $13.66 | 2024 | Onpattro |
| G Medical Diagnostic Services, INC. | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willie Session listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.